Clinical Success for Gene Editing, but at a Price None Could Afford
March 26, 2024 | Terry Sharrer
“Many CRISPR treatments are in trials, but in 2022, Vertex Pharmaceuticals, based in Boston, was first to bring one to regulators for approval. That treatment was for sickle-cell. After their bone marrow was edited, nearly all the patients who volunteered in the trial were pain free. Good news. But the expected price tag of the gene-editing treatment is $2 to $3 million.” MORE
Image Credit: TechnologyReview